Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 20/20 | 1.00 |
| ▸ | CDK9 | P50750 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 6/20 | 1.00 |
| ▸ | CCND1 | P24385 | 6/20 | 1.00 |
| ▸ | CDK7 | P50613 | 4/20 | 0.87 |
| ▸ | CCNH | P51946 | 4/20 | 0.87 |
| ▸ | CDK2 | P24941 | 4/20 | 0.78 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.78 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.78 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.78 |
| ▸ | CDK1 | P06493 | 2/20 | 0.78 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.78 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.78 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.78 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.78 |
| ▸ | CCNK | O75909 | 1/20 | 0.78 |
| ▸ | CDK14 | O94921 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CCNC | P24863 | 1/20 | 0.78 |
| ▸ | CDK17 | Q00537 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877660 | 1.00 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL21877738 | 1.00 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL21946521 | 0.93 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| Hydrochloric Acid SCHEMBL21877788 | 0.92 | CCNT1 (0.98) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL24174538 | 0.92 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL21877687 | 0.92 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL21946500 | 0.92 | CCNT1 (1.00) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL26871422 | 0.90 | CDK9 (0.82) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL26871420 | 0.90 | CDK9 (0.82) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL26871419 | 0.90 | CDK9 (0.82) | CCNT1CDK9CDK4CCND1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3873911-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | IGNOTA LABS LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | IGNOTA LABS LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | CDK9, CDK19, CDK7 | CCNT1 55/4885CDK9 1/4885CDK4 11/4885 |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | CCNT1 55/4885CDK9 1/4885CDK4 11/4885 |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CCNT1 40/4885CDK9 1/4885CDK4 12/4885 |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | CCNT1 55/4885CDK9 1/4885CDK4 11/4885 |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CCNT1 40/4885CDK9 1/4885CDK4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.